December 2013 Blog Posts (29)

Label Update for Cetuximab in Metastatic Colorectal Cancer in Patients With RAS Wild-Type Tumors Approved

The European Commission has approved and amendment of cetuximab (Erbitux®; Merck Serono/Merck*) product information, updating the indication for cetuximab to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

Colorectal cancer or CRC is the fourth most common…

Continue

Added by Editorial Team on December 23, 2013 at 10:30am — No Comments

The Business Of Prostate Cancer: Market Expected to Experience Approximately 10% Annual Growth through 2022

One of the world's leading market research and advisory firms for pharmaceutical and healthcare issues, Decision Resources, finds that the prostate cancer drug market will experience robust 10% annual growth through 2022. The growth is expected the world's major pharmaceutical markets, including United States, France, Germany, Italy, Spain, the United Kingdom and Japan, and will total $8.6 billion in…

Continue

Added by Editorial Team on December 19, 2013 at 5:30pm — No Comments

Novel Pre-surgery Treatment Combination is more Effective for Women With Triple-negative Breast Cancer

Adding the chemotherapy drug carboplatin (Paraplatin®; Bristol-Myers Squibb) and/or the antibody therapy bevacizumab (…

Continue

Added by Editorial Team on December 13, 2013 at 1:30pm — No Comments

Zoledronate Fails to Improve Outcomes for Patients with Chemo-resistant Breast Cancer

Breast cancer patients with residual disease after neo-adjuvant chemotherapy (NACT) are considered to have chemo-resistant cancer and adjuvant treatment with bisphosphonates, such as zoledronic acid or zoledronate (Zometa®; Novartis) is considered to reduce the relapse risk predominantly in estrogen-deprivated patients. However, initial results of a phase III clinical trial presented at the 36th San Antonio Breast Cancer…

Continue

Added by Editorial Team on December 13, 2013 at 11:00am — No Comments

Phase II Study Shows New, Innovative, Multidrug Therapy May Improve Outcomes for Women With Triple-negative Breast Cancer

According to data from the I-SPY 2 study (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), an innovative, multidrug, phase II breast cancer trial, presented at the 36th San Antonio Breast Cancer Symposium (SABCS), being held December 10–14, 2013 in San Antonio, Texas, adding carboplatin and the molecularly targeted drug veliparib, also known of ABT-888, a potent, orally bioavailable PARP-1/2 inhibitor to standard neo-adjuvant…

Continue

Added by Editorial Team on December 13, 2013 at 11:00am — No Comments

New Drug Combination Does Not Delay Progression of Advanced Breast Cancer

Anti-angiogenic strategies in metastatic breast cancer have demonstrated a number of modest improvements in progression-free survival. This observation warranted evaluation of new agents, such as the antibody ramucirumab (IMC-1121B; ImClone Systems/Eli Lilly and Company) in a placebo-controlled settings.

Ramucirumab is a fully human monoclonal antibody being developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2…

Continue

Added by Editorial Team on December 13, 2013 at 10:30am — No Comments

Metastatic Breast Cancer Patients With Elevated Circulating Tumor Cells(CTCs) do not Benefit from Changing Chemotherapy

Results of a phase III clinical trial presented at the 36th San Antonio Breast Cancer Symposium (SABCS), being held December 10–14, 2013 in San Antonio, Texas, shows that women with metastatic breast cancer who have elevated amounts of circulating tumor cells or CTCs in their blood after a first line of chemotherapy do not benefit from switching immediately to a different chemotherapy. The trial does not show an improvement in overall survival or time to progression.[1][2]…

Continue

Added by Editorial Team on December 13, 2013 at 9:30am — No Comments

Unique Gene Mutation Makes HER2- and Hormone Receptor-positive Breast Cancers Resistant to Treatment

Results presented at the San Antonio Breast Cancer Symposium (SABCS), being held December 10–14, 2013 in San Antonio, Texas, show that women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in a protein-coding gene called PIK3CA…

Continue

Added by Editorial Team on December 12, 2013 at 8:00am — No Comments

Anastrozole May Offer New Option for Breast Cancer Prevention

Cancer incidence among postmenopausal women at high risk of developing hormone receptor positive breast cancer has been significantly reduced by adjuvant treatment with the aromatase inhibitor (or AI) anastrozole (Arimidex®; AstraZeneca) The drug has shown significantly prolonged…

Continue

Added by Editorial Team on December 12, 2013 at 7:30am — No Comments

Exercise Helps Reduce Joint Pain Reported in Breast Cancer Survivors

Joint pain is included among the common side effects patients list for the treatment of their breast cancer with aromatase inhibitors or AIs such as anastrozole (Arimidex®; AstraZeneca), letrozole (…

Continue

Added by Editorial Team on December 12, 2013 at 7:30am — No Comments

Disease Progression Delayed for Subgroup With Metastatic Breast Cancer

Results from a phase II clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), being held December 10–14, 2013 in San Antonio, Texas, shows that adding dasatinib (Sprycel®; Bristol-Myers Squibb Company)

to a standard anti-hormone…

Continue

Added by Editorial Team on December 12, 2013 at 7:30am — No Comments

Re-examinging Study Results Shows a More Consistent Benefit of Breast Cancer Screening

An analysis of data from four major studies reviewing the benefits and harms of mammography screening suggest that the benefits are more consistent across these studies than previously understood.  The same data seems to  indicate a substantial reduction in breast cancer mortality with screening.  The results of the study were presented at the San Antonio Breast Cancer Symposium (SABCS), being held December 10–14, 2013 in San Antonio…

Continue

Added by Editorial Team on December 11, 2013 at 8:30pm — No Comments

Study Shows High Levels of Tumor-infiltrating Lymphocytes (TILs) may help Identify HER2+ Breast Cancer Patients Most Likely to Benefit From Trastuzumab

A study funded by the European Union Seventh Framework Program RESPONSIFY, the Breast Cancer Research Foundation, and the Fonds J.C. Heuson shows that women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from pre-surgery treatment with chemotherapy and trastuzumab (Herceptin®; Genentech), according to results presented here at the…

Continue

Added by Editorial Team on December 11, 2013 at 8:00pm — No Comments

Do Patients with Metastatic Breast Cancer Benefit From Surgery and Radiation After Chemotherapy?

Data presented at the San Antonio Breast Cancer Symposium (SABCS), being held December 10–14, 2013 in San Antonio, Texas, shows that the role of loco-regional treatment or LRT in women with metastatic breast cancer or MBC at first presentation, is debatable. According to data presented at the conference, after a response to initial chemotherapy, treatment with radiotherapy and surgical removal of the breast tumor and nearby lymph nodes…

Continue

Added by Editorial Team on December 11, 2013 at 3:30pm — No Comments

Avoiding Whole Breast Irradiation Option in Carefully Defined Groups of Older Patients

Results from the PRIME 2 trial presented at the San Antonio Breast Cancer Symposium SABCS), held December 10–14, 2013 indicate that the omission of radiotherapy is a reasonable option for women age 65 or older who receive hormone therapy after breast-conserving surgery for hormone receptor-positive, axillary node-negative breast cancer.[1]

“Radiotherapy has been known to reduce the risk of breast cancer recurrence three- to…

Continue

Added by Editorial Team on December 11, 2013 at 12:30pm — No Comments

Trastuzumab, Docetaxel and Carboplatin Therapy Highly Effective as Adjuvant Treatment Option for Patients With HER2-positive Breast Cancer

According to results from the BETH study presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10–14, 2013 in San Antonio, Texas, combining the chemotherapy drugs docetaxel (Taxotere®; Sanofi) and carboplatin with the humanized monoclonal antibody (mAb) trastuzumab (Herceptin®;…

Continue

Added by Editorial Team on December 11, 2013 at 10:00am — No Comments

Event-free and Overall Survival Results From NeoALTTO Trial vital for HER2+ Drug Development

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib (Tykerb®; GSK) and/or Trastuzumab (Herceptin®; Genentech) Treatment Optimization (NeoALTTO) trial, managed under the Breast International Group umbrella with two of its member groups, the BrEAST Data Centre and the SOLTI academic research group, were presented at at the annual San Antonio Breast…

Continue

Added by Editorial Team on December 11, 2013 at 9:00am — No Comments

Updated Results from a Phase II Trial of Brentuximab Vedotin Shows 42% Objective Response Rate in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

New, updated, data from a phase II clinical trial of brentuximab vedotin (Adcetris®; Seattle Genetics) in patients with diffuse large B-cell lymphoma or DLBCL and other B-cell non-Hodgkin lymphomas, demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results were presented at the 55th annual meeting of ASH®, the American Society of Hematology, held in New Orleans, Louisiana,…

Continue

Added by Editorial Team on December 10, 2013 at 9:30pm — No Comments

New Breast Cancer Chemo Response Test Predicts Benefit from DNA Damage-based Chemotherapy Drugs

By Michael Sloan and Richard Kennedy

There is little doubt that the age of personalized medicine is upon us. Companion diagnostics are now reaching the market and molecular testing in general is increasingly common, particularly in the…

Continue

Added by Editorial Team on December 10, 2013 at 2:00pm — No Comments

SABCS 2013 —What’s Hot?

Important research is slated to be presented at the 36th Annual San Antonio Breast Cancer Symposium (SABCS), which will be held on December 10 – 14, 2013 in San Antonio, Texas. The symposium will bring together physicians and academic (basic) scientists involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals from around the world to discuss what is new and where the field is headed. The…

Continue

Added by Editorial Team on December 9, 2013 at 11:30pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+